147 related articles for article (PubMed ID: 3802077)
41. Thiopurine methyltransferase regulation in rat kidney: immunoprecipitation studies.
Hernández JS; Van Loon JA; Otterness DM; Guerciolini R; Weinshilboum RM
Xenobiotica; 1991 Apr; 21(4):451-9. PubMed ID: 1897245
[TBL] [Abstract][Full Text] [Related]
42. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
Fichtinger-Schepman AM; Dijt FJ; Bedford P; van Oosterom AT; Hill BT; Berends F
IARC Sci Publ; 1988; (89):321-8. PubMed ID: 3198216
[TBL] [Abstract][Full Text] [Related]
43. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
Poirier MC; Shamkhani H; Reed E; Tarone RE; Gupta-Burt S
Prog Clin Biol Res; 1992; 374():197-212. PubMed ID: 1620704
[No Abstract] [Full Text] [Related]
44. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
[TBL] [Abstract][Full Text] [Related]
45. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals.
Litterst CL; LeRoy AF; Guarino AM
Cancer Treat Rep; 1979; 63(9-10):1485-92. PubMed ID: 498147
[TBL] [Abstract][Full Text] [Related]
46. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models.
Poirier MC; Reed E; Zwelling LA; Ozols RF; Litterst CL; Yuspa SH
Environ Health Perspect; 1985 Oct; 62():89-94. PubMed ID: 4085451
[TBL] [Abstract][Full Text] [Related]
47. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S
Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613
[TBL] [Abstract][Full Text] [Related]
48. Time course of the binding of platinum to subfractions of the kidney cytosol in the cisplatin-treated rat.
Mason R; Hogg S; Edwards IR
Res Commun Chem Pathol Pharmacol; 1986 Apr; 52(1):51-8. PubMed ID: 3715197
[TBL] [Abstract][Full Text] [Related]
49. [Histopathological study regarding the protective effect of elastase on cis-platinum-induced renal toxicity].
Suzuki M; Ohwada M; Sekiguchi I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):941-7. PubMed ID: 2778382
[TBL] [Abstract][Full Text] [Related]
50. Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.
Parti R; Wolf W
Cancer Chemother Pharmacol; 1990; 26(3):188-92. PubMed ID: 2357765
[TBL] [Abstract][Full Text] [Related]
51. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure.
Giurgiovich AJ; Diwan BA; Olivero OA; Anderson LM; Rice JM; Poirier MC
Carcinogenesis; 1997 Jan; 18(1):93-6. PubMed ID: 9054594
[TBL] [Abstract][Full Text] [Related]
52. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
Bergström P; Johnsson A; Bergenheim T; Henriksson R
J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475
[TBL] [Abstract][Full Text] [Related]
53. Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma.
Jones MM; Basinger MA
Anticancer Res; 1989; 9(6):1937-41. PubMed ID: 2627140
[TBL] [Abstract][Full Text] [Related]
54. Walker rat carcinoma cells are exceptionally sensitive to cis-diamminedichloroplatinum(II) (cisplatin) and other difunctional agents but not defective in the removal of platinum-DNA adducts.
Rawlings CJ; Roberts JJ
Mutat Res; 1986 Sep; 166(2):157-68. PubMed ID: 3762562
[TBL] [Abstract][Full Text] [Related]
55. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis.
Vrána O; Kiseleva VI; Poverenny AM; Brabec V
Eur J Pharmacol; 1992 May; 226(1):5-13. PubMed ID: 1397055
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure.
Giurgiovich AJ; Diwan BA; Lee KB; Anderson LM; Rice JM; Poirier MC
Carcinogenesis; 1996 Aug; 17(8):1665-9. PubMed ID: 8761423
[TBL] [Abstract][Full Text] [Related]
57. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Terheggen PM; Floot BG; Lempers EL; van Tellingen O; Begg AC; den Engelse L
Cancer Chemother Pharmacol; 1991; 28(3):185-91. PubMed ID: 1855275
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat.
Jones MM; Basinger MA; Mitchell WM; Bradley CA
Cancer Chemother Pharmacol; 1986; 17(1):38-42. PubMed ID: 3698175
[TBL] [Abstract][Full Text] [Related]
59. Escherichia coli DNA polymerase I: inherent exonuclease activities differentiate between monofunctional and bifunctional adducts of DNA and cis- or trans-diamminedichloroplatinum(II). An exonuclease investigation of the kinetics of the adduct formation.
Bernges F; Dörner G; Holler E
Eur J Biochem; 1990 Aug; 191(3):743-53. PubMed ID: 2167853
[TBL] [Abstract][Full Text] [Related]
60. The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Carcinogenesis; 1988 Oct; 9(10):1909-11. PubMed ID: 2458857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
